{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T01:47:03Z","timestamp":1782006423229,"version":"3.54.5"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The search for a preventive vaccine against HIV infection remains an ongoing challenge, indicating the need for novel approaches. Parainfluenza virus 5 (PIV5) is a paramyxovirus replicating in the upper airways that is not associated with any animal or human pathology. In animal models, PIV5-vectored vaccines have shown protection against influenza, RSV, and other human pathogens. Here, we generated PIV5 vaccines expressing HIV envelope (Env) and SIV Gag and administered them intranasally to macaques, followed by boosting with virus-like particles (VLPs) containing trimeric HIV Env. Moreover, we compared the immune responses generated by PIV5-SHIV prime\/VLPs boost regimen in na\u00efve vs a control group in which pre-existing immunity to the PIV5 vector was established. We demonstrate for the first time that intranasal administration of PIV5-based HIV vaccines is safe, well-tolerated and immunogenic, and that boosting with adjuvanted trimeric Env VLPs enhances humoral and cellular immune responses. The PIV5 prime\/VLPs boost regimen induced robust and durable systemic and mucosal Env-specific antibody titers with functional activities including ADCC and neutralization. This regimen also induced highly polyfunctional antigen-specific T cell responses. Importantly, we show that diminished responses due to PIV5 pre-existing immunity can be overcome in part with VLP protein boosts. Overall, these results establish that PIV5-based HIV vaccine candidates are promising and warrant further investigation including moving on to primate challenge studies.<\/jats:p>","DOI":"10.3389\/fimmu.2021.623996","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T05:29:36Z","timestamp":1614230976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Parainfluenza Virus 5 Priming Followed by SIV\/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates"],"prefix":"10.3389","volume":"12","author":[{"given":"Peng","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Dienger-Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley C.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karnail","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar R. Deb","family":"Adhikary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Villinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral Therapy for the Prevention of HIV-1 Transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMc1110588","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0152-1","article-title":"Antiretroviral therapy for prevention is a combination strategy","volume":"10","author":"McNairy","year":"2013","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B4","article-title":"Global HIV & AIDS statistics fact sheet","year":"2018"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60821-6","article-title":"Global epidemiology of HIV infection in men who have sex with men","volume":"380","author":"Beyrer","year":"2012","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMms1513641","article-title":"Applying Public Health Principles to the HIV Epidemic\u2013How Are We Doing","volume":"373","author":"Frieden","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu420","article-title":"Ending the global HIV\/AIDS pandemic: the critical role of an HIV vaccine","volume":"59","author":"Fauci","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.367.6478.611","article-title":"Combo of two HIV vaccines fails its big test","volume":"367","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.018","article-title":"A brief history of the global effort to develop a preventive HIV vaccine","volume":"31","author":"Esparza","year":"2013","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1573395514666180605092054","article-title":"Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission","volume":"15","author":"Kozlowski","year":"2019","journal-title":"Curr Immunol Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.12.005","article-title":"Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge","volume":"362","author":"Tompkins","year":"2007","journal-title":"Virology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/vr.98.15.301","article-title":"Isolation of parainfluenza virus SV5 from dogs with respiratory disease","volume":"98","author":"Cornwell","year":"1976","journal-title":"Vet Rec"},{"key":"B16","article-title":"Canine parainfluenza-Bordetella bronchiseptica vaccine immunogenicity","volume":"42","author":"Chladek","year":"1981","journal-title":"Am J Vet Res"},{"key":"B17","article-title":"Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough)","volume":"42","author":"Kontor","year":"1981","journal-title":"Am J Vet Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e1965","DOI":"10.1002\/rmv.1965","article-title":"Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases","volume":"28","author":"Chen","year":"2018","journal-title":"Rev Med Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00559","DOI":"10.1128\/JVI.00559-17","article-title":"Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after In Vitro and In Vivo Passage","volume":"91","author":"Phan","year":"2017","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02886-12","article-title":"A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein","volume":"87","author":"Chen","year":"2013","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00120-13","article-title":"Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00560-17","article-title":"Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge","volume":"91","author":"Phan","year":"2017","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.124","article-title":"Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02330-12","article-title":"Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB\/c mice","volume":"87","author":"Mooney","year":"2013","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/aid.2011.0053","article-title":"How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development","volume":"28","author":"Klasse","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/382088","article-title":"Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein","volume":"189","author":"Wright","year":"2004","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq175","article-title":"A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers","volume":"203","author":"Spearman","year":"2011","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz008","article-title":"Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period","volume":"219","author":"Spearman","year":"2019","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.056","article-title":"Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes","volume":"163","author":"de Taeye","year":"2015","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.immuni.2017.05.007","article-title":"Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches","volume":"46","author":"Pauthner","year":"2017","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2018.11.011","article-title":"Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers","volume":"50","author":"Pauthner","year":"2019","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01163-16","article-title":"Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA\/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques","volume":"90","author":"Iyer","year":"2016","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.62.5.1530-1534.1988","article-title":"Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination","volume":"62","author":"Rooney","year":"1988","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2307\/1592516","article-title":"Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine","volume":"44","author":"Swayne","year":"2000","journal-title":"Avian Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01274-08","article-title":"Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice","volume":"77","author":"Leong","year":"2009","journal-title":"Infect Immun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e50144","DOI":"10.1371\/journal.pone.0050144","article-title":"Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5","volume":"7","author":"Chen","year":"2012","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e01884","DOI":"10.1128\/JVI.01884-19","article-title":"A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques","volume":"94","author":"Singh","year":"2020","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.024","article-title":"TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)","volume":"23","author":"Weeratna","year":"2005","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00126334-200008010-00001","article-title":"Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody","volume":"24","author":"Kozlowski","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nature06890","article-title":"Rapid cloning of high-affinity human monoclonal antibodies against influenza virus","volume":"453","author":"Wrammert","year":"2008","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01844-16","article-title":"Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5alpha Restrictive Macaques","volume":"91","author":"Kasturi","year":"2017","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1002890","DOI":"10.1371\/journal.ppat.1002890","article-title":"ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge","volume":"8","author":"Alpert","year":"2012","journal-title":"PloS Pathog"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01289-13","article-title":"Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6822(03)00467-7","article-title":"Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core","volume":"314","author":"Hammonds","year":"2003","journal-title":"Virology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"Baba","year":"2000","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/5568","article-title":"Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1\/SIV chimeric virus infections of macaque monkeys","volume":"5","author":"Shibata","year":"1999","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of broadly neutralizing antibodies for HIV-1 prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00410-10","article-title":"Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian\/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques","volume":"84","author":"Xiao","year":"2010","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clim.2007.04.004","article-title":"Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression","volume":"124","author":"Peretz","year":"2007","journal-title":"Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1086\/526786","article-title":"Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy","volume":"197","author":"Pereyra","year":"2008","journal-title":"J Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02968-13","article-title":"Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point","volume":"88","author":"Riou","year":"2014","journal-title":"J Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1371\/journal.pmed.0050100","article-title":"Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells","volume":"5","author":"Streeck","year":"2008","journal-title":"PloS Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1001273","DOI":"10.1371\/journal.ppat.1001273","article-title":"Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection","volume":"7","author":"Ferrari","year":"2011","journal-title":"PloS Pathog"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.020","article-title":"Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge","volume":"33","author":"Sholukh","year":"2015","journal-title":"Vaccine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06812-11","article-title":"Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge","volume":"86","author":"Xiao","year":"2012","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.01.015","article-title":"Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges","volume":"34","author":"Bomsel","year":"2011","journal-title":"Immunity"},{"key":"B65","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/08830180802684331","article-title":"Mucosal immunity and protection against HIV\/SIV infection: strategies and challenges for vaccine design","volume":"28","author":"Demberg","year":"2009","journal-title":"Int Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/C2013-0-18914-3","article-title":"Vaccine immunology (General Aspects of Vaccination)","author":"Siegrist","year":"2018","journal-title":"Vaccines"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.1058915","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.623996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T05:29:40Z","timestamp":1614230980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.623996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2021.623996"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.623996","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"623996"}}